At the time of writing, Ascendis Pharma A/S ADR [ASND] stock is trading at $152.61, up 0.71%. An important factor to consider is whether the stock is rising or falling in short-term value. The ASND shares have lost -1.61% over the last week, with a monthly amount glided 21.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on January 07, 2025, when UBS initiated its Buy rating and assigned the stock a price target of $196. Previously, Oppenheimer upgraded its rating to Outperform on September 05, 2024, and kept the price target unchanged to $180. On June 25, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $175 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $200 on May 31, 2024. Jefferies initiated its recommendation with a Buy and recommended $150 as its price target on December 20, 2023. In a note dated April 05, 2023, Oppenheimer downgraded an Perform rating on this stock.
For the past year, the stock price of Ascendis Pharma A/S ADR fluctuated between $111.09 and $161.00. Currently, Wall Street analysts expect the stock to reach $208.86 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $152.61 at the most recent close of the market. An investor can expect a potential return of 36.86% based on the average ASND price forecast.
Analyzing the ASND fundamentals
According to Ascendis Pharma A/S ADR [NASDAQ:ASND], the company’s sales were 391.88M for trailing twelve months, which represents an 25.27% jump. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -0.77%, Pretax Profit Margin comes in at -1.03%, and Net Profit Margin reading is -1.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is 1.98 and Total Capital is -1.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -8.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 148.53 points at the first support level, and at 144.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 156.34, and for the 2nd resistance point, it is at 160.07.
Ratios To Look Out For
It is important to note that Ascendis Pharma A/S ADR [NASDAQ:ASND] has a current ratio of 1.17. On the other hand, the Quick Ratio is 0.84, and the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 23.30.
Transactions by insiders
Recent insider trading involved SINGEL STINA, Officer, that happened on Feb 20 ’25 when 2729.0 shares were purchased. Officer, SMITH SCOTT THOMAS completed a deal on Feb 20 ’25 to buy 10000.0 shares. Meanwhile, Officer PEDERSEN ANNI LOTTE KIRSTINE S bought 39375.0 shares on Feb 19 ’25.
